Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Implantica AG
  6. News
  7. Summary
    IMP A SDB   SE0014855029

IMPLANTICA AG

(IMP A SDB)
  Report
Delayed Nasdaq Stockholm  -  03:00 2022-09-28 am EDT
41.00 SEK   -1.20%
08/23Implantica AG Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
CI
05/11Implantica AG Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
03/07Implantica Ag Announces Launch of Refluxstop™ in Uk
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Implantica AG Announces Filing of Comprehensive eHealth Patent Applications for Its Platform Technology

02/21/2022 | 02:00am EDT

Implantica AG (publ) announced that it has concluded an extensive eHealth patent filing that exceeded 25'000 pages, the culmination of a full year's work of Implantica's team and patent attorneys. The filing encompasses 59 new patent applications focused on Implantica's eHealth platform and a broad range of applications. This comprehensive filing represents a considerable strengthening and term-extension of Implantica's patent protection.

The patent applications will provide fundamental coverage for the eHealth platform in general and extend the scope and term of the patent protection for the pipeline products. This filing will ­ in the years to come ­ be divided into several hundred individual patent applications, building patent protection for the platform and the pipeline products as the development progresses. The large eHealth application comprised 1'950 pages and consisted of 596 pages of drawings, which is approximately 100-fold the size of a standard patent.

During 2021, Implantica validated 824 issued patents in total in various countries.


© S&P Capital IQ 2022
All news about IMPLANTICA AG
08/23Implantica AG Reports Earnings Results for the Second Quarter and Six Months Ended June..
CI
05/11Implantica AG Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
03/07Implantica Ag Announces Launch of Refluxstop™ in Uk
CI
02/21Implantica AG Announces Filing of Comprehensive eHealth Patent Applications for Its Pla..
CI
02/18Implantica AG Reports Earnings Results for the Fourth Quarter Ended December 31, 2021
CI
02/18Implantica AG Reports Earnings Results for the Full Year Ended December 31, 2021
CI
02/01Implantica Appoints New COO
MT
02/01Implantica AG Appoints Paul Meadas as Chief Operating Officer
CI
2021Implantica Successfully Performs Cadaver Implantations of Pipeline Products and Several..
CI
2021Implantica AG Reports Earnings Results for the Third Quarter and Nine Months Ended Sept..
CI
More news
Financials
Sales 2022 1,87 M 1,79 M 1,79 M
Net income 2022 -24,0 M -23,0 M -23,0 M
Net cash 2022 54,9 M 52,7 M 52,7 M
P/E ratio 2022 -9,20x
Yield 2022 -
Capitalization 1 076 M 1 032 M 1 032 M
EV / Sales 2022 547x
EV / Sales 2023 77,0x
Nbr of Employees 29
Free-Float 4,86%
Chart IMPLANTICA AG
Duration : Period :
Implantica AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends IMPLANTICA AG
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Last Close Price 3,80 €
Average target price 9,82 €
Spread / Average Target 159%
EPS Revisions
Managers and Directors
Peter Forsell Chief Executive Officer
Andreas Öhrnberg Chief Financial Officer
Liselott Kilaas Chairman
Paul Mead Chief Operating Officer
Johan Bojs Vice Chairman
Sector and Competitors
1st jan.Capi. (M$)
IMPLANTICA AG-36.15%1 032
SHOCKWAVE MEDICAL, INC.46.26%9 371
NOVOCURE LIMITED-1.93%7 816
MASIMO CORPORATION-52.18%7 355
PENUMBRA, INC.-36.48%6 981
GETINGE AB-53.25%4 469